GGPoker Partners With Legendary deadmau5 For Record-Breaking $150M GG Spring Festival
29.3.2021 23:26:00 EEST | Business Wire | Press release
GGPoker today reveals that it will partner with world-famous electronic music producer deadmau5 for the poker room’s upcoming GG Spring Festival tournament series.
The Canadian superstar will kick the festival off in style by hosting an opening night party on April 3, which includes an exclusive music set streamed on GGPoker.TV and a $100K Freeroll Houseparty. GGPoker players will also have the opportunity to play with - and knock out - the artist in his own $10K GG Legends Bounty feat. deadmau5 on April 10.
The full GG Spring Festival will guarantee at least $150 million in prizes, the highest series guarantee amount in online poker history. The tournament series runs from April 4 through April 25, and includes more than 300 individual events, with buy-ins set at ‘Low’, ‘Medium’ and ‘High’, designed to suit every bankroll.
GG Spring Festival headline events include:
- Main Event-H - No Limit Hold’em - $1,500 buy-in - $10M Guaranteed
- Super Millions Main Event-H - No Limit Hold’em - $10,300 buy-in - $10M Guaranteed
- Headliner-M - No Limit Hold’em - $400 buy-in - $2.5M Guaranteed
In total, 39 festival events boast a prize pool guarantee of $1M or higher. The festival will also include community-focused special events and streamed DJs/artists.
“This is going to be the biggest online poker event of all time and will blow a lot of people’s minds,” said Daniel Negreanu, GGPoker Ambassador. “From the deadmau5-hosted launch party and other festival elements to the massive headline event guarantees, it’s a true poker party from start to finish, and I can’t wait for it to get underway!”
Some of the most exciting GG Spring Festival final table action will be broadcast on GGPoker.TV, with shows scheduled on April 6, April 20 and April 27.
New GGPoker players are eligible to claim the poker room’s Welcome Bonus, earn even more rewards with the Honeymoon for Newcomers promotion and automatically join GGPoker’s Fish Buffet loyalty program, with regular cash prizes on offer.
For further details on the GG Spring Festival, please visit: https://www.contents.ggnetwork-contents.com/ggsf-2021
About GGPoker: GGPoker is one of the world’s leading online poker rooms, with a global player base. It offers a range of innovative games and features such as the patented Rush & Cash poker, All-In or Fold, Flip & Go, Spin & Gold, integrated staking platform, SnapCam video messaging, the ability to squeeze your hole cards, PokerCraft, and Smart HUD, all designed to enhance gaming experiences and make poker more fun than ever. In 2020, GGPoker hosted WSOP tournaments, including the world record-breaking WSOP Online main event and the WSOP 2020 Main Event.
Find out more about GGPoker at GGPoker.com and on Facebook and Twitter.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210329005749/en/
Contact information
Paul Burke at press@ggpoker.com.
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Carnegie Mellon University and Cleveland Clinic Develop AI System to Interpret Cardiac MRI Scans with Enhanced Accuracy21.5.2026 15:05:00 EEST | Press release
A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521762286/en/ A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. The novel system, called CMR-CLIP, is designed to interpret cardiac MRI scans by connecting moving images of the heart with corresponding clinical radio
The Live Moment Effect: Genius Sports and MediaScience Study Finds Specific Moments in Live Sports Can Double Unaided Brand Recall21.5.2026 15:00:00 EEST | Press release
Genius Sports Limited (NYSE: GENI), a global leader in real-time sports data, today released new biometric research conducted with MediaScience showing that ads delivered immediately after emotionally heightened moments in live sports can double unaided brand recall. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521475265/en/ The Live Moment Effect report from Genius Sports and MediaScience. The study, The Live Moment Effect, finds that advertising effectiveness is significantly influenced by a viewer’s emotional state immediately before an ad is shown. In controlled biometric testing, ads shown after high-intensity sporting moments, such as near-scoring plays or crucial momentum shifts, delivered approximately double the unaided brand recall of baseline conditions. The Moment Before the Ad Matters The research challenges long-held assumptions about media value, showing that not all impressions are equal. Live sports rem
Merck Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer21.5.2026 15:00:00 EEST | Press release
Merck, a leading science and technology company, today announced that the first patient has been dosed in the Phase 3 PROCEADE®-CRC-03 trial (NCT07549412). The study is evaluating precemtabart tocentecan (Precem‑TcT), a potential first‑in‑class investigational anti‑CEACAM5 antibody‑drug conjugate (ADC), for the treatment of metastatic colorectal cancer (mCRC). “Leveraging our novel payload‑linker technology, Precem‑TcT is the first CEACAM5‑targeted ADC in clinical studies with an exatecan payload, rationally designed for stability and enhanced cancer cell killing activity,” said David Weinreich, MD, MBA, Global Head of R&D and Chief Medical Officer for the Healthcare business of Merck. “The Phase 3 study and the enrollment of the first patient with Precem-TcT build on the Company’s more than 20 years of expertise in colorectal cancer, and highlight our commitment to advancing differentiated ADCs for heavily pretreated patients with limited treatment options.” The PROCEADE®-CRC-03 study
Baszucki Group Funds Oxford University Clinical Trial of Ketogenic Therapy for Early Psychosis21.5.2026 14:00:00 EEST | Press release
Baszucki Group today announced a £1.17 million grant to support a randomized controlled trial at the University of Oxford assessing the feasibility, safety, and efficacy of a ketogenic diet for patients at clinical high risk of psychosis (CHR-P). Researchers will test this nutritional therapy's ability to improve patients' mental and physical health. This project builds on a growing body of research suggesting the potential of metabolic therapies in treating serious mental illness. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521877110/en/ Baszucki Group Funds £1.17 Million for University of Oxford Trial of Ketogenic Therapy for Early Psychosis Psychotic disorders carry a massive personal burden and are associated with a lower life expectancy. Psychosis does not develop immediately, but typically emerges following a period of early, subtle symptoms. Individuals in this stage, classified as CHR-P, represent a critical pr
SINOVAC Announces Extension of Deadline to Submit Payment Instructions for Previously Declared Special Cash Dividend21.5.2026 13:30:00 EEST | Press release
Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it has extended the deadline for shareholders and nominee brokers to submit payment instructions relating to the Company’s previously declared special cash dividend. The Company previously announced a special cash dividend of US$55.00 per common share, payable to valid holders of the Company’s common shares as of the close of business on May 23, 2025 ET. The Company previously informed shareholders that completed instruction materials were to be submitted prior to December 31, 2025 in order to facilitate receipt of the dividend. The Company has now extended that submission deadline to June 30, 2026. Shareholders and nominee brokers that have not yet submitted their instruction materials are reminded to do so on or before June 30, 2026 in order to facilitate payment of the dividend. If you have any questions regarding the process you need to un
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom